IMMUNOVANT INC (IMVT:NASDAQ)
$39.71 -1.38 (-3.3585%)
Analysed IMMUNOVANT INC (IMVT:NASDAQ) News Sources
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
23-05-2026
fool.com
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
23-05-2026
fool.com
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
24-05-2026
fool.com
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
24-05-2026
fool.com
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
28-05-2026
yahoo.com
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
02-06-2026
yahoo.com
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
05-06-2026
yahoo.com
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
12-06-2026
yahoo.com
Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
18-06-2026
yahoo.com
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
19-06-2026
yahoo.com
What is the current price of IMMUNOVANT INC (IMVT:NASDAQ)?
The current price of IMMUNOVANT INC (IMVT:NASDAQ) is $39.71.
IMMUNOVANT INC (IMVT:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNOVANT INC (IMVT:NASDAQ) since the previous trading day is $-1.38.
IMMUNOVANT INC (IMVT:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNOVANT INC (IMVT:NASDAQ) since the previous trading day is -3.3585%.
What is the most recent average sentiment score for IMMUNOVANT INC (IMVT:NASDAQ)?
The most recent average sentiment score for IMMUNOVANT INC (IMVT:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for IMMUNOVANT INC (IMVT:NASDAQ)?
The most recent sentiment for IMMUNOVANT INC (IMVT:NASDAQ) is .
SEC-8K** Filing Available For IMMUNOVANT INC (IMVT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.